Previous 10 | Next 10 |
TAMPA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL ® (bupivacaine lipo...
Pacira BioSciences, Inc. (PCRX) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive Officer Charlie Reinhart – Chief Financial Officer Conference Call Participants Dav...
Pacira BioSciences press release (NASDAQ:PCRX): Q1 Non-GAAP EPS of $0.64 misses by $0.19. Revenue of $158M (+32.8% Y/Y) beats by $2.92M. Adjusted EBITDA was $53.8 million, or $1.20 per share (basic) and $1.16 per share (diluted) in the first quarter of 2022, compared to $36.2 million, or $0.8...
-- First quarter revenue of $158 million, up 33% over prior year -- -- Strong topline performance delivers net income and significantly positive adjusted EBITDA -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Pacira BioScience...
Rengenxbio (NASDAQ: RGNX) , Corcept Therapeutics (NASDAQ: CORT) , and Pacira BioSciences (NASDAQ: PCRX) are all small-cap healthcare stocks with market caps below $3.5 billion. While the share prices of many companies in this sector have plummeted recently, these...
TAMPA, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 4, 2022. Following the release, the company will host a live conference call a...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Small cap growth stocks entered bear market territory dur...
Pacira BioSciences (NASDAQ:PCRX) on Tuesday has announced preliminary revenue estimate of $157.4-$158.4M for Q1 2022, up from $119M revenue reported last year. It includes: EXPAREL product sales, $129.2M; ZILRETTA product revenue following Flexion Therapeutics acquisition, $23-$24M; and&...
TAMPA, Fla., April 12, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary revenues of $157.4 to $158.4 million for the first quarter of 2022, comp...
TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21 st Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Tuesday, April 12, 2022. Live audio of the even...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...